Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Theravance Biopharma (TBPH) Return on Sales (2016 - 2025)

Historic Return on Sales for Theravance Biopharma (TBPH) over the last 13 years, with Q3 2025 value amounting to 0.18%.

  • Theravance Biopharma's Return on Sales rose 9300.0% to 0.18% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.27%, marking a year-over-year increase of 10500.0%. This contributed to the annual value of 0.99% for FY2024, which is 300.0% down from last year.
  • Per Theravance Biopharma's latest filing, its Return on Sales stood at 0.18% for Q3 2025, which was up 9300.0% from 2.09% recorded in Q2 2025.
  • Theravance Biopharma's Return on Sales' 5-year high stood at 74.46% during Q3 2022, with a 5-year trough of 2.12% in Q1 2023.
  • For the 5-year period, Theravance Biopharma's Return on Sales averaged around 4.24%, with its median value being 0.18% (2025).
  • Per our database at Business Quant, Theravance Biopharma's Return on Sales surged by 729000bps in 2022 and then plummeted by -750300bps in 2023.
  • Quarter analysis of 5 years shows Theravance Biopharma's Return on Sales stood at 1.72% in 2021, then plummeted by -85bps to 0.27% in 2022, then tumbled by -282bps to 0.48% in 2023, then tumbled by -154bps to 1.23% in 2024, then soared by 115bps to 0.18% in 2025.
  • Its Return on Sales stands at 0.18% for Q3 2025, versus 2.09% for Q2 2025 and 0.88% for Q1 2025.